These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22194990)

  • 1. Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy.
    Gallardo E; de Luna N; Diaz-Manera J; Rojas-García R; Gonzalez-Quereda L; Flix B; de Morrée A; van der Maarel S; Illa I
    PLoS One; 2011; 6(12):e29061. PubMed ID: 22194990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysferlin quantification in monocytes for rapid screening for dysferlinopathies.
    Sánchez-Chapul L; Ángel-Muñoz MD; Ruano-Calderón L; Luna-Angulo A; Coral-Vázquez R; Hernández-Hernández Ó; Magaña JJ; León-Hernández SR; Escobar-Cedillo RE; Vargas S
    Muscle Nerve; 2016 Dec; 54(6):1064-1071. PubMed ID: 27104310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal expression of dysferlin in skeletal muscle and monocytes supports primary dysferlinopathy in patients with one mutated allele.
    Meznaric M; Gonzalez-Quereda L; Gallardo E; de Luna N; Gallano P; Fanin M; Angelini C; Peterlin B; Zidar J
    Eur J Neurol; 2011 Jul; 18(7):1021-3. PubMed ID: 21658164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and epigenetic determinants of low dysferlin expression in monocytes.
    Gallardo E; Ankala A; Núñez-Álvarez Y; Hegde M; Diaz-Manera J; Luna ND; Pastoret A; Suelves M; Illa I
    Hum Mutat; 2014 Aug; 35(8):990-7. PubMed ID: 24838345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DYSF mutation analysis in a group of Chinese patients with dysferlinopathy.
    Zhao Z; Hu J; Sakiyama Y; Okamoto Y; Higuchi I; Li N; Shen H; Takashima H
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1234-7. PubMed ID: 23254335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report of an adolescent girl with limb-girdle muscular dystrophy type 2B - the usefulness of muscle protein immunostaining in the diagnosis of dysferlinopathies.
    Szymanska S; Rokicki D; Karkucinska-Wieckowska A; Szymanska-Debinska T; Ciara E; Ploski R; Grajkowska W; Pronicki M
    Folia Neuropathol; 2014; 52(4):452-6. PubMed ID: 25574751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysferlin expression in monocytes: a source of mRNA for mutation analysis.
    De Luna N; Freixas A; Gallano P; Caselles L; Rojas-García R; Paradas C; Nogales G; Dominguez-Perles R; Gonzalez-Quereda L; Vílchez JJ; Márquez C; Bautista J; Guerrero A; Salazar JA; Pou A; Illa I; Gallardo E
    Neuromuscul Disord; 2007 Jan; 17(1):69-76. PubMed ID: 17070050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysferlin function in skeletal muscle: Possible pathological mechanisms and therapeutical targets in dysferlinopathies.
    Cárdenas AM; González-Jamett AM; Cea LA; Bevilacqua JA; Caviedes P
    Exp Neurol; 2016 Sep; 283(Pt A):246-54. PubMed ID: 27349407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysferlin regulates cell adhesion in human monocytes.
    de Morrée A; Flix B; Bagaric I; Wang J; van den Boogaard M; Grand Moursel L; Frants RR; Illa I; Gallardo E; Toes R; van der Maarel SM
    J Biol Chem; 2013 May; 288(20):14147-14157. PubMed ID: 23558685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle.
    Klinge L; Harris J; Sewry C; Charlton R; Anderson L; Laval S; Chiu YH; Hornsey M; Straub V; Barresi R; Lochmüller H; Bushby K
    Muscle Nerve; 2010 Feb; 41(2):166-73. PubMed ID: 20082313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New aspects on patients affected by dysferlin deficient muscular dystrophy.
    Klinge L; Aboumousa A; Eagle M; Hudson J; Sarkozy A; Vita G; Charlton R; Roberts M; Straub V; Barresi R; Lochmüller H; Bushby K
    J Neurol Neurosurg Psychiatry; 2010 Sep; 81(9):946-53. PubMed ID: 19528035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel diagnostic features of dysferlinopathies.
    Rosales XQ; Gastier-Foster JM; Lewis S; Vinod M; Thrush DL; Astbury C; Pyatt R; Reshmi S; Sahenk Z; Mendell JR
    Muscle Nerve; 2010 Jul; 42(1):14-21. PubMed ID: 20544924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunolabelling and flow cytometry as new tools to explore dysferlinopathies.
    Wein N; Krahn M; Courrier S; Bartoli M; Salort-Campana E; Nguyen K; Fernandez C; Pouget J; Fossat C; Depetris D; Leturcq F; Cau P; Levy N
    Neuromuscul Disord; 2010 Jan; 20(1):57-60. PubMed ID: 19854055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late onset in dysferlinopathy widens the clinical spectrum.
    Klinge L; Dean AF; Kress W; Dixon P; Charlton R; Müller JS; Anderson LV; Straub V; Barresi R; Lochmüller H; Bushby K
    Neuromuscul Disord; 2008 Apr; 18(4):288-90. PubMed ID: 18396043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.
    Azakir BA; Di Fulvio S; Kinter J; Sinnreich M
    J Biol Chem; 2012 Mar; 287(13):10344-10354. PubMed ID: 22318734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptomatic dysferlin gene mutation carriers: characterization of two cases.
    Illa I; De Luna N; Domínguez-Perles R; Rojas-García R; Paradas C; Palmer J; Márquez C; Gallano P; Gallardo E
    Neurology; 2007 Apr; 68(16):1284-9. PubMed ID: 17287450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1α,25(OH)(2)-Vitamin D3 increases dysferlin expression in vitro and in a human clinical trial.
    De Luna N; Díaz-Manera J; Paradas C; Iturriaga C; Rojas-García R; Araque J; Genebriera M; Gich I; Illa I; Gallardo E
    Mol Ther; 2012 Oct; 20(10):1988-97. PubMed ID: 22910291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The absence of dysferlin induces the expression of functional connexin-based hemichannels in human myotubes.
    Cea LA; Bevilacqua JA; Arriagada C; Cárdenas AM; Bigot A; Mouly V; Sáez JC; Caviedes P
    BMC Cell Biol; 2016 May; 17 Suppl 1(Suppl 1):15. PubMed ID: 27229680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysferlin interacts with calsequestrin-1, myomesin-2 and dynein in human skeletal muscle.
    Flix B; de la Torre C; Castillo J; Casal C; Illa I; Gallardo E
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1927-38. PubMed ID: 23792176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic overview of blood-based dysferlin protein assay for dysferlinopathies.
    Ankala A; Nallamilli BR; Rufibach LE; Hwang E; Hegde MR
    Muscle Nerve; 2014 Sep; 50(3):333-9. PubMed ID: 24488599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.